Literature DB >> 25663410

Body weight-based natalizumab treatment in adult patients with multiple sclerosis.

M Tanaka1, M Kinoshita, J F Foley, K Tanaka, J Kira, W M Carroll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25663410     DOI： 10.1007/s00415-015-7655-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  4 in total

1.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Extended interval dosing of natalizumab: a two-center, 7-year experience.

Authors:  Roberto Bomprezzi; Siddharama Pawate
Journal:  Ther Adv Neurol Disord       Date:  2014-09       Impact factor: 6.570

Review 3.  Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Authors:  David Hunt; Gavin Giovannoni
Journal:  Pract Neurol       Date:  2012-02

4.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910
  4 in total
  9 in total

1.  Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Authors:  Kumar Kandadi Muralidharan; Deb Steiner; Diogo Amarante; Pei-Ran Ho; Dan Mikol; Jacob Elkins; Meena Subramanyam; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-01       Impact factor: 2.745

2.  Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.

Authors:  Michael Auer; Angelika Bauer; Antonia Oftring; Dagmar Rudzki; Harald Hegen; Gabriel Bsteh; Franziska Di Pauli; Klaus Berek; Anne Zinganell; Thomas Berger; Markus Reindl; Florian Deisenhammer
Journal:  CNS Drugs       Date:  2022-09-29       Impact factor: 6.497

3.  Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients.

Authors:  Masami Tanaka; Kaho Yokoyama
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-02-19

4.  The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

Authors:  Zoé LE van Kempen; Cyra E Leurs; Birgit I Witte; Annick de Vries; Mike P Wattjes; Theo Rispens; Joep Killestein
Journal:  Mult Scler       Date:  2017-05-09       Impact factor: 6.312

5.  Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.

Authors:  Gerd Haga Bringeland; Nello Blaser; Kjell-Morten Myhr; Christian Alexander Vedeler; Sonia Gavasso
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-02-04

6.  Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.

Authors:  Undine Proschmann; Hernan Inojosa; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

7.  Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.

Authors:  Giuseppe Magro; Stefania Barone; Federico Tosto; Antonio De Martino; Domenico Santange Lo; Lucia Manzo; Angelo Pascarella; Pietro Bruno; Marilisa Pasquale; Antonio Gambardella; Paola Valentino
Journal:  J Neurol       Date:  2022-10-13       Impact factor: 6.682

8.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Authors:  T Sehr; U Proschmann; K Thomas; M Marggraf; E Straube; H Reichmann; A Chan; T Ziemssen
Journal:  J Neuroinflammation       Date:  2016-06-27       Impact factor: 8.322

9.  Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.

Authors:  Júlia Granell-Geli; Cristina Izquierdo-Gracia; Ares Sellés-Rius; Aina Teniente-Serra; Silvia Presas-Rodríguez; María José Mansilla; Luis Brieva; Javier Sotoca; María Alba Mañé-Martínez; Ester Moral; Irene Bragado; Susan Goelz; Eva Martínez-Cáceres; Cristina Ramo-Tello
Journal:  J Pers Med       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.